Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder

Journal of Urology

Volumn 173, Issue 5, 2005, Pages 1518-1525

  Shariat, Shahrokh F ^a   Zippe, Craig ^b   Lübecke, Gerson ^c   Boman, Hans ^d   Sanchez Carbayo, Marta ^e,f   Casella, Roberto ^g   Mian, Christine ^d,h   Friedrich, Martin G ⁱ   Eissa, Sanaa ^j   Akaza, Hideyuki ^k   Sawczuk, Ihor ^l   Serretta, Vincenzo ^m   Huland, Hartwig ^d,i   Hedelin, Hans ^d,i   Rupesh, Raina ^b   Miyanaga, Naoto ^k   Sagalowsky, Arthur I ^a   Wians Jr , Frank ^a   Roehrborn, Claus G ^a   Lotan, Yair ^a   Perrotte, Paul ⁿ   Benayoun, Serge ⁿ   Marberger, Michael J ^h   Karakiewicz, Pierre I ⁿ   more..

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d Kärnsjukhuset Skövde ^*  (Italy)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF BASEL   (Switzerland)

^h UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF HAMBURG   (Germany)

^j AIN SHAMS UNIVERSITY   (Egypt)

^k UNIVERSITY OF TSUKUBA   (Japan)

^l University of Tsukuba ^*  (United States)

^m UNIVERSITY OF PALERMO   (Italy)

ⁿ UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

Bladder neoplasms; Neoplasm staging; Nomograms; Nuclear matrix protein 22

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE CYTOLOGY; VALIDATION PROCESS;

EID: 20244362785     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000154696.48217.75     Document Type: Article

References (21)

1. Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Hafermann, M. D. et al: Superficial bladder cancer: progression and recurrence. J Urol, 130: 1083, 1983
2. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A. et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 163: 1124, 2000
3. Kesari, D., Kovisman, V., Cytron, S. and Benjamin, J.: Effects on pain and anxiety of patients viewing their cystoscopy in addition to a detailed explanation: a controlled study. BJU Int, 92: 751, 2003
4. Wiener, H. G., Vooijs, G. P. and van't Hof-Grootenboer, B.: Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol, 37: 163, 1993
5. Lotan, Y. and Roehrborn, C. G.: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology, 61: 109, 2003
6. Shariat, S. F., Casella, R., Monoski, M. A., Sulser, T., Gasser, T. C. and Lerner, S. P.: The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol, 170: 2244, 2003
7. Shariat, S. F., Casella, R., Wians, F. H., Jr., Ashfaq, R., Balko, J., Sulser, T. et al: Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol, 45: 304, 2004
8. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L. et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol, 156: 363, 1996
9. Shariat, S. F., Casella, R., Khoddami, S. M., Hernandez, G., Sulser, T., Gasser, T. C. et al: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol, 171: 626, 2004
10. Sharma, S., Zippe, C. D., Pandrangi, L., Nelson, D. and Agarwal, A.: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol, 162: 53, 1999
11. Sanchez-Carbayo, M., Herrero, E., Megias, J., Mira, A. and Soria, F.: Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int, 84: 706, 1999
12. Miyanaga, N., Akaza, H., Tsukamoto, T., Ishikawa, S., Noguchi, R., Ohtani, M. et al: Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol, 6: 173, 1999
13. Serretta, V., Lo Presti, D., Vasile, P., Gange, E., Esposito, E. and Menozzi, I.: Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology, 52: 793, 1998
14. Stampfer, D. S., Carpinito, G. A., Rodriguez-Villanueva, J., Willsey, L. W., Dinney, C. P., Grossman, H. B. et al: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol, 159: 394, 1998
15. Casella, R., Huber, P., Blochlinger, A., Stoffel, F., Dalquen, P., Gasser, T. C. et al: Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol, 164: 1926, 2000
16. Efron, B. and Tibshirani, R. J.: The bootstrap estimate of standard error. In: An Introduction to the Bootstrap. New York, Chapman & Hall, p. 45, 1998
17. Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. and Scardino, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
18. Graefen, M., Karakiewicz, P. I., Cagiannos, I., Quinn, D. I., Henshall, S. M., Grygiel, J. J. et al: International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol, 20: 3206, 2002
19. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C. et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst, 81: 1879, 1989
20. Kattan, M. W.: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst, 95: 634, 2003
21. Kattan, M. W., Shariat, S. F., Andrews, B., Zhu, K., Canto, E., Matsumoto, K. et al: The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol, 21: 3573, 2003